Themis Medicare Faces Financial Struggles Amidst Declining Sales and Profitability Metrics

Themis Medicare, a small-cap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment reflecting its ongoing challenges. The company reported a negative financial performance for the quarter ending September 2025, with a notable score improvement over the past three months.
Key metrics indicate that while Themis Medicare achieved its highest operating cash flow at Rs 34.71 crore and a strong dividend payout ratio of 19.24%, several areas remain concerning. The profit before tax (PBT) has significantly declined, showing a drop of 152% compared to the previous four-quarter average, resulting in a loss of Rs 6.69 crore. Additionally, the profit after tax (PAT) fell to Rs -3.62 crore, down 59.6% from prior averages.

Sales figures also reflect a downturn, with net sales at Rs 77.99 crore, a decrease of 17.9%. Other indicators, such as the return on capital employed (ROCE) at -3.47% and cash and cash equivalents at a low of Rs 12.75 crore, further highlight the company's struggles.

In terms of market performance, Themis Medicare has faced significant declines over various time frames, particularly year-to-date and over the past year, contrasting sharply with the Sensex returns. This disparity underscores the challenges the company faces in regaining market confidence.